Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
  • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/02—Ortho- or ortho- and peri-condensed systems
  • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
  • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
  • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
  • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Definitions

• the present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti- infective medicament.
• Tigecycline (4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-9-[[[(1 ,1- dimethylethyl)amino]acetyl]amino]-1 ,4, 4a, 5, 5a, 6, 11 ,12a-octahydro-3, 10, 12, 12a-tetrahydroxy- 1 ,11-dioxo-2-naphthacenecarboxamide, is a 9-t-butylglycylamido derivative of minocycline (Merck Index 14 th Edition, monograph number 9432, CAS Registry Number 220620-09-7).
• Tigecycline is more active against tetracycline- resistant strains and also more tolerable.
• Tigecycline possesses activity against bacterial isolates containing the two major determinants responsible for tetracycline-resistance: ribosomal protection and active efflux of the drug out of the bacterial cell.
• Tigecycline possesses broad spectrum activity, e.g. it is active against gram-positive pathogens (e.g. methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci), gram-negative pathogens (e.g.
• WO 2005/056538, WO 2006/130418, WO 2006/130431 , WO 2006/130500 and WO 2006/130501 disclose Tigecycline, acid addition salts of Tigecycline and processes for the preparation of the same as well. However, in literature no crystalline Tigecycline hydrochloride is described.
• Tigecycline is available on the market as lyophilized powder for injection, the originator is Wyeth. During the formulation process Tigecycline is first dissolved in water and then lyophilized. Therefore a crystalline form of Tigecycline or an alternative crystalline acid addition salt of Tigecycline should show high water solubility.
• the commercial Tygacil ® 2 nd generation product contains, according to the originator, following ingredients:
• crystalline solids have improved chemical and physical stability over the amorphous form and forms with low crystallinity, therefore crystalline Tigecycline hydrochloride is more preferred than amorphous Tigecycline hydrochloride.
• crystalline Tigecycline hydrochloride with suitable solubility and stability properties for the formulation of an anti-infective medicament.
• the present invention refers to crystalline form A of Tigecycline hydrochloride.
• Crystalline form A of Tigecycline hydrochloride can be described by an X-ray powder diffraction pattern comprising peaks at 2-theta angles of 7.6° ⁇ 0.2°, 9.1 ⁇ 0.2°, 12.2 ⁇ 0.2°, 13.7 ⁇ 0.2°, 15.2 ⁇ 0.2°, 18.0 ⁇ 0.2°, 20.6 ⁇ 0.2°, 22.8 ⁇ 0.2° and 23.7 ⁇ 0.2°.
• crystalline form A of Tigecycline hydrochloride can be described by an infrared spectrum comprising peaks at wavenumbers of 3443 ⁇ 2 cm “1 , 3278 ⁇ 2 cm “1 , 2393 ⁇ 2 cm “1 , 1689 ⁇ 2 cm “1 , 1651 ⁇ 2 cm “1 , 1544 ⁇ 2 cm “1 , 1362 ⁇ 2 cm “1 , 1271 ⁇ 2 cm “1 , 1130 ⁇ 2 cm “1 , 1050 ⁇ 2 cm “1 , 871 ⁇ 2 cm “1 and 808 ⁇ 2 cm “1 .
• a first process for the preparation of crystalline form A of Tigecycline hydrochloride comprising the steps of: a) stirring a suspension of Tigecycline in a suitable solvent at room temperature; b) adding hydrochloric acid to the suspension; c) isolating crystalline form A of Tigecycline hydrochloride;
• a second process for the preparation of crystalline form A of Tigecycline hydrochloride comprising the steps of: a) dissolving Tigecycline in a suitable solvent at a temperature ranging from room temperature to the boiling point of the used solvent; b) adding hydrochloric acid to the solution; c) cooling down the obtained suspension to room temperature or below; d) isolating crystalline form A of Tigecycline hydrochloride; is subject matter of the present invention as well.
• the present invention refers to crystalline form B of Tigecycline hydrochloride.
• Crystalline form B of Tigecycline hydrochloride can be described by an X-ray powder diffraction pattern comprising peaks at 2-theta angles of 5.8° ⁇ 0.2°, 7.0 ⁇ 0.2°, 9.1 ⁇ 0.2°, 9.7 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.5 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.3 ⁇ 0.2°, 19.6 ⁇ 0.2°, 22.4 ⁇ 0.2°, 25.5 ⁇ 0.2°, 27.1 ⁇ 0.2° and 28.5 ⁇ 0.2°.
• crystalline form B of Tigecycline hydrochloride can be described by an infrared spectrum comprising peaks at wavenumbers of 3365 ⁇ 2 cm “1 , 3228 ⁇ 2 cm “1 , 1685 ⁇ 2 cm “1 , 1648 ⁇ 2 cm “1 , 1545 ⁇ 2 cm “1 , 1360 ⁇ 2 cm “1 , 1263 ⁇ 2 cm “1 , 1204 ⁇ 2 cm “1 and 872 ⁇ 2 cm “1 .
• a process for the preparation of crystalline form B of Tigecycline hydrochloride comprising the steps of: a) stirring a mixture of Tigecycline and methylenchloride; b) adding hydrochloric acid ; c) stirring the solution at room temperature or below to effect crystallization of crystalline form B of Tigecycline hydrochloride; d) isolating crystalline form B of Tigecycline hydrochloride;
• the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament.
• compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount.
• the present invention refers to the use of crystalline form A of Tigecycline hydrochloride as an anti-infective medicament.
• Figure 1 X-ray powder diffraction pattern of crystalline form A of Tigecycline hydrochloride
• Figure 2 Infrared spectrum of crystalline form A of Tigecycline hydrochloride
• Figure 3 Differential Scanning Calorimetric curve of crystalline form A of Tigecycline hydrochloride
• Figure 4 X-ray powder diffraction pattern of crystalline form B of Tigecycline hydrochloride
• Figure 5 Infrared spectrum of crystalline form B of Tigecycline hydrochloride
• Figure 6 Differential Scanning Calorimetric curve of crystalline form B of Tigecycline hydrochloride
• amorphous relates to solid material which lacks a regular crystalline structure.
• room temperature indicates that the applied temperature is not critical and that no exact temperature value has to be kept. Usually, “room temperature” is understood to mean temperatures of about 15°C to about 25°C [see e.g. EU Pharmacopoeia 6.0, 1.2 (2008)].
• concentrated hydrochloric acid relates to hydrochloric acid having a hydrochloride concentration of 37 %.
• the present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to processes for the preparation thereof.
• Figure A Chemical structure of Tigecycline hydrochloride
• the crystalline forms A and B of Tigecycline hydrochloride may be characterized e.g. by a typical X-ray powder diffraction pattern, an infrared spectrum or a differential scanning calorimetric curve. Each of these characteristics on its own is sufficient to unambiguously define and identify the crystalline form of Tigecycline hydrochloride but they also may be combined with each other.
• the present invention relates to crystalline form A of Tigecycline hydrochloride characterized by an X-ray powder diffraction pattern with peaks at 2-theta angles of 7.6° ⁇ 0.2°, 9.1 ⁇ 0.2°, 12.2 ⁇ 0.2°, 13.7 ⁇ 0.2°, 15.2 ⁇ 0.2°, 18.0 ⁇ 0.2°, 20.6 ⁇ 0.2°, 22.8 ⁇ 0.2° and 23.7 ⁇ 0.2°.
• a characteristic X-ray powder diffraction pattern of crystalline form A of Tigecycline hydrochloride is shown in Figure 1 and some characteristic peaks are listed in Table 2.
• the present invention relates to crystalline form A of Tigecycline hydrochloride characterized by an X-ray powder diffraction pattern substantially in accordance with Table 2 and Figure 1.
• Crystalline form A of Tigecycline hydrochloride also may be characterized by a typical infrared spectrum as shown in Figure 2. Accordingly in a further preferred embodiment, the present invention relates to crystalline form A of Tigecycline hydrochloride characterized by an infrared spectrum substantially in accordance with Figure 2. Characteristic bands are present at wavenumbers of 3443 ⁇ 2 cm “1 , 3278 ⁇ 2 cm “1 , 2393 ⁇ 2 cm “1 , 1689 ⁇ 2 cm “1 , 1651
• crystalline form A of Tigecycline hydrochloride may be characterized by a typical differential scanning calorimetric curve as shown in Figure 3.
• the curve displays a first endothermic peak with a maximum at about 59 0 C, which may be due to desolvation.
• the second endothermic peak with a maximum at about 232 0 C may be due to the melting process.
• a melting point of 232 0 C proves high thermal stability.
• the present invention relates to crystalline form A of Tigecycline hydrochloride characterized by a differential scanning calorimetric curve substantially in accordance with Figure 3.
• the present invention provides a first process for the preparation of crystalline form A of Tigecycline hydrochloride, comprising the steps of: a) stirring a suspension of Tigecycline in a suitable solvent at room temperature; b) adding hydrochloric acid to the suspension; c) isolating crystalline form A of Tigecycline hydrochloride;
• the present invention provides a second process for the preparation of crystalline form A of Tigecycline hydrochloride, comprising the steps of: a) dissolving Tigecycline in a suitable solvent at a temperature ranging from room temperature to the boiling point of the used solvent; b) adding hydrochloric acid to the solution; c) cooling down the obtained suspension to room temperature or below; d) isolating crystalline form A of Tigecycline hydrochloride;
• Any form of Tigecycline may be used in step a) of the above processes, e. g. amorphous forms, crystalline forms, mixtures of amorphous and crystalline forms, mixtures of different crystalline forms, hydrates or solvates.
• Suitable crystalline forms may be forms I to V of WO 2006/128150, forms I and Il of WO 2007/127292 or mixtures thereof.
• the concentration of Tigecycline in step a) of the above processes depends on the form of Tigecycline and on the solvent used. Generally the second process asks for lower concentrations than the first, because prior to the acid addition Tigecycline is completely dissolved.
• Tigecycline preferably is used at a concentration ranging from 5 to 200 g/L, more preferably from 10 to 50 g/L. Concentrations preferably ranging from 5 to 50 g/L, most preferably from 5 to 15 g/L are applied in the second process.
• the temperature in step a) of the above second process may vary. However, the temperature is chosen such that at a given concentration of a particular form of Tigecycline in a particular solvent a clear solution is obtained. Therefore it may become necessary to heat the solvent to reflux.
• Suitable solvents in step a) of the above processes are for example ketones such as acetone or ethylmethylketone, nitriles such as acetonitrile, esters such as methylacetate, ethylacetate and isopropylacetate and ethers such as tetrahydrofuran and 1 ,4-dioxane.
• ketones such as acetone or ethylmethylketone
• nitriles such as acetonitrile
• esters such as methylacetate, ethylacetate and isopropylacetate
• ethers such as tetrahydrofuran and 1 ,4-dioxane.
• mixtures of polar and apolar solvents such as dimethylformamid/ diethylether.
• the solvent is chosen from acetone or acetonitrile, most preferably the solvent is acetonitrile.
• hydrochloric acid may be used in step b) of the above described processes.
• Either diluted or concentrated hydrochloric acid having a concentration ranging from 3 to 38 % can be employed.
• hydrochloric acid having a concentration of about 10 to 37 %, most preferably having a concentration of about 18 % is used.
• the ratio of Tigecycline to hydrochloric acid used may vary. Typically about 0.9 to about 1.5 equivalents, most preferably 1.0 to 1.4 equivalents of hydrochloric acid to 1 equivalent Tigecycline (mol : mol) will be employed. However, the ratio should be chosen such that no free base is present anymore ( ⁇ 1.0 mol equivalent HCI in crystal structure) and that the amount of undesired byproducts is as low as possible. In addition the ratio also depends on the concentration of the hydrochloric acid used.
• 1.0 equivalent hydrochloric acid is preferably used in order to find at least 1.0 mol equivalent HCI in the crystal lattice of Tigecycline hydrochloride and keeping undesired by products under an acceptable limit.
• Table 3 shows the amount of hydrochloride in the crystal structure of Tigecycline hydrochloride and the undesired byproducts found in dependence on the amount and concentration of hydrochloric acid used. The inventors found 0.9 to 1.4 mol equivalents HCI in the crystal lattice, therefore form A is a monohydrochloride.
• Form A of Tigecycline hydrochloride is also a particularly suitable form for the isolation of Tigecycline hydrochloride in the last step of the synthesis.
• the water content of crystalline form A of Tigecycline hydrochloride may vary from about 0 - 6.0 % e.g. the water content is 0 % when stored at 1.7 % relative humidity at 25 0 C, 2.7 % when stored at 42.7 % relative humidity at 25 0 C and 5.8 % when stored at 80 % relative humidity at 25 0 C.
• Tigecycline hydrochloride form A crystallizes in small ellipsoidal needles and columns having a length ranging from about 5 - 20 ⁇ m.
• the present invention relates to crystalline form B of Tigecycline hydrochloride characterized by an X-ray powder diffraction pattern with peaks at 2-theta angles of 5.8° ⁇ 0.2°, 7.0 ⁇ 0.2°, 9.1 ⁇ 0.2°, 9.7 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.5 ⁇ 0.2°, 17.3 ⁇ 0.2°, 18.3 ⁇ 0.2°, 19.6 ⁇ 0.2°, 22.4 ⁇ 0.2°, 25.5 ⁇ 0.2°, 27.1 ⁇ 0.2° and 28.5 ⁇ 0.2°.
• a characteristic X-ray powder diffraction pattern of crystalline form B of Tigecycline hydrochloride is shown in Figure 4 and some characteristic peaks are listed in Table 4.
• the present invention relates to crystalline form B of Tigecycline hydrochloride characterized by an X-ray powder diffraction pattern substantially in accordance with Table 4 and Figure 4.
• Crystalline form B of Tigecycline hydrochloride also may be characterized by a typical infrared spectrum as shown in Figure 5. Accordingly in a further preferred embodiment, the present invention relates to crystalline form B of Tigecycline hydrochloride characterized by an infrared spectrum substantially in accordance with Figure 5. Characteristic bands are present at wavenumbers of 3365 ⁇ 2 cm “1 , 3228 ⁇ 2 cm “1 , 1685 ⁇ 2 cm “1 , 1648 ⁇ 2 cm “1 , 1545 ⁇ 2 cm “1 , 1360 ⁇ 2 cm “1 , 1263 ⁇ 2 cm “1 , 1204 ⁇ 2 cm “1 and 872 ⁇ 2 cm “1 .
• the DSC curve in Figure 6 shows a broad endotherm from the beginning of the measurement until about 170 0 C with a maximum at about 92 0 C. This peak may be due to desolvation.
• the present invention provides a process for the preparation of crystalline form B of Tigecycline hydrochloride, comprising the steps of: a) stirring a mixture of Tigecycline and methylenchloride; b) adding hydrochloric acid ; c) stirring the solution at room temperature or below to effect crystallization of crystalline form B of Tigecycline hydrochloride; d) isolating crystalline form B of Tigecycline hydrochloride;
• Tigecycline may be used in step a) of the above process, e. g. amorphous forms, crystalline forms, mixtures of amorphous and crystalline forms, mixtures of different crystalline forms, hydrates or solvates. Suitable crystalline forms may be forms I to V of WO 2006/128150, forms I and Il of WO 2007/127292 or mixtures thereof.
• the concentration of Tigecycline in step a) of the above process depends on the form of Tigecycline used. Tigecycline preferably is used at a concentration ranging from 5 to 100 g/L, more preferably from 5 to 50 g/L and most preferably the concentration ranges from 5 g/L to 15 g/L
• crystalline form B of Tigecycline hydrochloride does only crystallize from methylenchloride.
• solvents like for example alcohols such as ethanol, isopropanol or 2-butanol, ketones such as acetone or ethylmethylketone, nitriles such as acetonitrile, esters such as methylacetate, ethylacetate and isopropylacetate or ethers such as tetrahydrofuran and 1 ,4-dioxane crystalline form B of Tigecycline hydrochloride does not crystallize.
• the inventors of the present invention found out that the methylenechloride content of crystalline form B of Tigecycline hydrochloride ranges from 0.4 to 0.5 mol (analyzed by GC, Table 5).
• hydrochloric acid can be used in step b) of the above described process.
• Either diluted or concentrated hydrochloric acid having a concentration in the range from 3 to 38 % can be employed.
• hydrochloric acid having a concentration of about 10 to 37 % most preferably having a concentration of about 18 % is used.
• the ratio of Tigecycline to hydrochloric acid used may vary. Typically about 0.9 to about 1.5 equivalents, most preferably 1.0 to 1.4 equivalents of hydrochloric acid to 1 equivalent Tigecycline (mol : mol) will be employed. Table 5 displays that the amount of hydrochloride in the crystal lattice is 1.0 mol equivalent no matter if 1.0 or 1.4 mol equivalent hydrochloric acid are used. Therefore crystalline form B of Tigecycline hydrochloride is a monohydrochloride.
• Table 5 Varying amounts of HCI, methylenchloride and undesired byproducts depending on the amount of hydrochloric acid applied
• the crystalline form B of Tigecycline hydrochloride crystallizes in small needles having a length ranging from about 10 - 15 ⁇ m.
• the finished dosage form contains lyophilized amorphous Tigecycline respectively Tigecycline hydrochloride. Before lyophilizing, Tigecycline respectively Tigecycline hydrochloride is dissolved in water, thus water solubility is an important factor to consider.
• Table 6 displays the solubility data of the different crystalline forms of Tigecycline free base compared with these of crystalline forms A and B of Tigecycline hydrochloride. Crystalline form A of Tigecycline hydrochloride clearly shows the highest water solubility.
• crystalline form A shows higher water solubility than forms I, II, III, IV and V of WO 2006/128150 and also higher water solubility than crystalline forms I and Il of WO 2007/127292.
• form B of Tigecycline hydrochloride shows lower solubility than form A. Nevertheless form B nearly shows the same water solubility as the most soluble free base, namely form IV of WO 2006/128150. Consequently the crystalline forms of Tigecycline hydrochloride of the present invention, especially form A, are particularly suitable forms for the lyophilization process in order to formulate an anti-infective medicament.
• the crystalline forms of Tigecycline hydrochloride of the present invention represent thermodynamically stable forms, which means they do not convert into other crystalline or amorphous forms when storing them even at elevated temperatures.
• the crystalline forms A and B of Tigecycline hydrochloride of the present invention did not convert into other crystalline or amorphous forms after storing for 7 days at 80 0 C.
• Tigecycline must be available in a physical stable form as well, in order to avoid degradation and as a consequence the building of undesired byproducts.
• Table 7 displays the stability data of the different crystalline forms of Tigecycline free base compared with the stability data of the crystalline forms of Tigecycline hydrochloride from the present invention. After storing for 7 days at 80 0 C one can see that forms I and Il of WO 2006/128150 show a tremendous increase in total impurities. All the other crystalline forms of Tigecycline respectively Tigecycline hydrochloride which have been tested showed satisfying stability data when considering that 7 days at 80 0 C are extreme conditions, which an active pharmaceutical ingredient will never experience in his life-cycle under ordinary circumstances. For example the 4-Epi-Tigecycline content of crystalline form A of Tigecycline hydrochloride practically did not change and also the increase of total impurities was low.
• crystalline forms A and B of Tigecycline hydrochloride of the present invention show better physical stability than amorphous Tigecycline hydrochloride.
• amorphous Tigecycline hydrochloride was prepared by lyophilization and stored for about 9 months at room temperature. The batch showed a 4-Epi-Tigecycline content of 19.56 % and 21.55 % total impurities. Therefore amorphous Tigecycline hydrochloride is not suitable as an intermediate for the formulation of an anti-infective medicament, due to the low stability.
• crystalline forms A and B of Tigecycline hydrochloride, especially form A possess excellent water solubility and good physical and thermodynamical stability and are therefore suitable intermediates for the formulation of an anti-infective medicament.
• Water solubility is an important factor to consider as Tigecycline respectively Tigecycline hydrochloride is dissolved in water before lyophilization during the formulation process. That's why the crystalline forms of the present invention, especially form A which shows the highest water solubility, are particularly suitable intermediates for the formulation of an anti- infective medicament.
• thermodynamical and physical stabilities of the crystalline forms of the present invention were satisfying as well.
• the two crystalline forms of the present invention neither showed a noticeable increase in impurities nor a conversion of the crystal structure after storing at extreme conditions.
• novel crystalline form A of Tigecycline hydrochloride of the present invention may be used alone as antibacterial drug or in the form of a suitable pharmaceutical composition containing the novel form.
• the present invention relates to the use of crystalline form A of Tigecycline hydrochloride as an anti-infective medicament.
• novel forms A and B of Tigecycline hydrochloride are particularly useful for the treatment of infections. Therefore, the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament.
• compositions comprising an effective amount of crystalline form A of Tigecycline hydrochloride.
• X-ray powder diffraction pattern (XRPD) were collected on a Unisantis XMD 300 X-ray powder diffractometer with a position sensitive detector in parallel beam optics using the following acquisition conditions: tube anode: Cu , 40 kV, 0.8 mA; 3 - 43° theta/2theta; simultaneous detection of regions of 10° per step with detector resolution 1024, counting time 300 seconds per step.
• Samples were measured at room temperature in a standard sample holder on a rotating sample spinner.
• a typical precision of the 2-theta values is in the range of ⁇ about 0.2° 2-Theta.
• a diffraction peak that appears at 5.0° 2-theta can appear between 4.8° and 5.2° 2-theta on most X-ray diffractometers under standard conditions.
• Infrared spectra were collected on a MKII Golden GateTM Single Reflection Diamond ATR (attenuated total reflection) cell with a Bruker Tensor 27 FTIR spectrometer with 4 cm "1 resolution at ambient conditions.
• IR Infrared spectra
• a spatula tip of a sample was applied to the surface of the diamond in powder form. Then the sample was pressed onto the diamond with a sapphire anvil and the spectrum was recorded. A spectrum of the clean diamond was used as background spectrum.
• a typical precision of the wavenumber values is in the range of about ⁇ 2 cm ⁇ 1 .
• an infrared peak that appears at 1716 cm “1 can appear between 1714 and 1718 cm “1 on most infrared spectrometers under standard conditions.
• DSC Differential scanning calorimetry
• a suspension of Tigecycline was prepared by mixing a solid Tigecycline sample and acetonitrile in amounts as shown in Table A. The mixture was than stirred for 1 hour at room temperature before 5 N hydrochloric acid was added in amounts corresponding to Table A. After stirring for about 20 hours the solid was filtered off and dried at room temperature under vacuum to obtain crystalline form A of Tigecycline hydrochloride.
• a suspension of Tigecycline was prepared by mixing a solid Tigecycline sample and acetonitrile in amounts as shown in Table B. The mixture was than stirred for about 1 hour at room temperature before concentrated hydrochloric acid was added in amounts corresponding to Table B. After stirring for about 4 hours the solid was filtered off and dried at room temperature under vacuum to obtain crystalline form A of Tigecycline hydrochloride.
• a solution of Tigecycline was prepared by mixing 500 mg of a solid Tigecycline sample with 10 ml acetone. Within about 5 minutes a precipitate appeared and the suspension was further stirred for 1.75 h. 143 ⁇ l (1.0 mol equivalent) 5N hydrochloric acid were added to the suspension and stirring was continued for 5 hours. Finally the solid was filtered off, washed with acetone and dried at room temperature under vacuum to obtain 440 mg (97 % yield) of crystalline form A of Tigecycline hydrochloride (98.73 % purity by HPLC).
• Tigecycline (Tygacil® 50mg, Wyeth®, powder for infusion) were dissolved in 500 ⁇ l ethylmethylketone and the solution was stirred at room temperature. After about one minute an orange precipitate appeared (essentially pure form III). Afterwards 8.4 mg (1 eq) concentrated hydrochloric acid were added and the suspension was stirred for approximately 3 hours. The solid was filtered off, washed with ethylmethylketone and dried under vacuum at room temperature to obtain 43.7 mg (82 % yield) of crystalline form A of Tigecycline hydrochloride.
• a suspension of Tigecycline was prepared by mixing a solid Tigecycline sample and methylenchloride in amounts as shown in Table C. The mixture was than stirred at room temperature and 5N hydrochloric acid was added in amounts corresponding to Table C. After stirring for about 92 hours the solid was filtered off and dried at room temperature under vacuum to obtain crystalline form B of Tigecycline hydrochloride.
• a saturated solution of Tigecycline respectively Tigecycline hydrochloride in distilled water was prepared and the suspension was stirred at room temperature for 30 minutes with a stirring speed of 1000 U/min. The suspension was filtrated through a 0.45 ⁇ m filter. Finally the resulting solution was diluted 10000-fold and measured against water at a wavelength of 347 nm.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Communicable Diseases (AREA)
• Pharmacology & Pharmacy (AREA)
• Oncology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=39186791

Family Applications (1)

Country Status (9)

Families Citing this family (4)

Citations (2)

Family Cites Families (9)

• 2008
  • 2008-11-12 CA CA2704536A patent/CA2704536C/en not_active Expired - Fee Related
  • 2008-11-12 SI SI200831397T patent/SI2220033T1/sl unknown
  • 2008-11-12 EP EP08849962.9A patent/EP2220033B1/en active Active
  • 2008-11-12 ES ES08849962.9T patent/ES2532880T3/es active Active
  • 2008-11-12 JP JP2010533564A patent/JP5574967B2/ja active Active
  • 2008-11-12 CN CN200880116248.7A patent/CN101861300B/zh active Active
  • 2008-11-12 US US12/742,706 patent/US8252946B2/en active Active
  • 2008-11-12 WO PCT/EP2008/065398 patent/WO2009062963A1/en not_active Ceased
• 2010
  • 2010-04-29 IL IL205451A patent/IL205451A0/en active IP Right Grant
• 2012
  • 2012-07-17 US US13/550,665 patent/US20130012481A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events